
Opinion|Videos|May 15, 2024
Key Findings from MAJIC-PV
A comprehensive overview of key findings from the MAJIC-PV trial investigating ruxolitinib in patients with polycythemia vera, highlighting efficacy and symptom improvement.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
4
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
5

























